Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM).

Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM).

The urokinase plasminogen activator receptor (uPAR) plays a role in tumor progression and has been proposed as a target for the treatment of cancer. We recently described the development of a novel humanized monoclonal antibody that targets uPAR and has anti-tumor activity in multiple xenograft anim...

Full description

Bibliographic Details
Main Authors: Xiang Xu, Yuan Cai, Ying Wei, Fernando Donate, Jose Juarez, Graham Parry, Liqing Chen, Edward J Meehan, Richard W Ahn, Andrey Ugolkov, Oleksii Dubrovskyi, Thomas V O'Halloran, Mingdong Huang, Andrew P Mazar
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3897428?pdf=render

Similar Items

Similar Items